de With Katja, Steib-Bauert Michaela, Knoth Holger, Dörje Frank, Strehl Egid, Rothe Ulrich, Maier Ludwig, Kern Winfried V
Center for Infectious Diseases and Travel Medicine, University Hospital, D-79106 Freiburg, Germany.
BMC Clin Pharmacol. 2005 Feb 10;5:1. doi: 10.1186/1472-6904-5-1.
Sales data indicate a major increase in the prescription of antifungal drugs in the last two decades. Many new agents for systemic use that only recently have become available are likely to be prescribed intensively in acute care hospitals. Sales data do not adequately describe the developments of drug use density. Given the concerns about the potential emergence of antifungal drug resistance, data on drug use density, however, may be valuable and are needed for analyses of the relationship between drug use and antifungal resistance.
Hospital pharmacy records for the years 2001 to 2003 were evaluated, and the number of prescribed daily doses (PDD, defined according to locally used doses) per 100 patient days were calculated to compare systemic antifungal drug use density in different medical and surgical service areas between five state university hospitals.
The 3-year averages in recent antifungal drug use for the five hospitals ranged between 8.6 and 29.3 PDD/100 patient days in the medical services (including subspecialties and intensive care), and between 1.1 and 4.0 PDD/100 patient days in the surgical services, respectively. In all five hospitals, systemic antifungal drug use was higher in the hematology-oncology service areas (mean, 48.4, range, 24 to 101 PDD/100 patient days, data for the year 2003) than in the medical intensive care units (mean, 18.3, range, 10 to 33 PDD/100) or in the surgical intensive care units (mean, 10.7, range, 6 to 18 PDD/100). Fluconazole was the most prescribed antifungal drug in all areas. In 2003, amphotericin B consumption had declined to 3 PDD/100 in the hematology-oncology areas while voriconazole use had increased to 10 PDD/100 in 2003.
Hematology-oncology services are intense antifungal drug prescribing areas. Fluconazole and other azol antifungal drugs are the most prescribed drugs in all patient care areas while amphotericin B use has considerably decreased. The data may be useful as a benchmark for focused interventions to improve prescribing quality.
销售数据表明,在过去二十年中抗真菌药物的处方量大幅增加。许多仅在最近才可用的新型全身用药物可能会在急症医院中大量使用。销售数据并不能充分描述药物使用密度的发展情况。然而,鉴于对抗真菌药物耐药性可能出现的担忧,药物使用密度数据可能很有价值,并且对于分析药物使用与抗真菌耐药性之间的关系是必要的。
评估了2001年至2003年的医院药房记录,并计算了每100个患者日的规定日剂量(PDD,根据当地使用剂量定义),以比较五家州立大学医院不同医疗和外科服务区域的全身抗真菌药物使用密度。
五家医院近期抗真菌药物使用的3年平均值在医疗服务(包括专科和重症监护)中为每100个患者日8.6至29.3 PDD,在外科服务中为每100个患者日1.1至4.0 PDD。在所有五家医院中,血液肿瘤服务区域的全身抗真菌药物使用量(2003年数据,平均值为48.4,范围为24至101 PDD/100个患者日)高于医疗重症监护病房(平均值为18.3,范围为10至33 PDD/100)或外科重症监护病房(平均值为10.7,范围为6至18 PDD/100)。氟康唑是所有区域处方最多的抗真菌药物。2003年,血液肿瘤区域的两性霉素B消耗量降至每100个患者日3 PDD,而伏立康唑在2003年的使用量增加至每100个患者日10 PDD。
血液肿瘤服务是抗真菌药物处方量较大的领域。氟康唑和其他唑类抗真菌药物是所有患者护理区域处方最多的药物,而两性霉素B的使用量已大幅下降。这些数据可作为有针对性干预措施的基准,以提高处方质量。